GlassScriptPhysician profile
Lawrence Ukpong
NPI 1376700807
$12,855.67
in general payments reported to CMS, 2019-2025
38 companies · $2,788 in 2025
The $2,788 reported for 2025 was more than what 87% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,105 · 2020: $1,369 · 2021: $1,386 · 2022: $941 · 2023: $1,323 · 2024: $1,944 · 2025: $2,788.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,356 · Travel and Lodging: $2,699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,356.27 |
| Travel and Lodging | $2,698.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,757.84 | 2021-2025 | Micra, Linq II, Azure Xt Dr Mri Surescan |
| Medtronic Vascular, INC. | $1,735.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $944.64 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $944.62 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $809.62 | 2019-2024 | Farxiga |
| Merck Sharp & Dohme LLC | $569.39 | 2021-2025 | Verquvo, Lagevrio |
| Amgen INC. | $565.32 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $436.80 | 2019-2025 | Lifevest |
| Lundbeck LLC | $399.91 | 2019-2021 | |
| Boston Scientific Corporation | $360.55 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $312.22 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $233.14 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.17 | 2019-2024 | Jardiance |
| Abbott Laboratories | $177.33 | 2020-2025 | Gallant, Assurity, Esprit |
| Regeneron Healthcare Solutions, INC. | $143.72 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $130.49 | 2025 | |
| Novo Nordisk INC | $124.69 | 2020-2025 | Wegovy |
| Kiniksa Pharmaceuticals, LTD. | $117.99 | 2021-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $112.71 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $94.11 | 2019-2021 | |
| Acist Medical Systems, INC. | $78.59 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $67.91 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $63.68 | 2022 | |
| Shockwave Medical, INC | $61.19 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Alnylam Pharmaceuticals INC. | $59.52 | 2021-2024 | Amvuttra |
| Cardiovascular Systems INC. | $54.78 | 2020-2023 | Diamondback Peripheral |
| Esperion Therapeutics, INC. | $52.02 | 2021-2022 | |
| Scpharmaceuticals INC. | $43.52 | 2024-2025 | |
| Inari Medical, INC. | $35.02 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Vital Connect, INC | $32.42 | 2025 | Vitalpatch Rtm |
| Kestra Medical Technology Services, INC. | $27.01 | 2025 | Assure Wcd |
| Ethicon US, LLC | $20.33 | 2022 | |
| Bridgebio Pharma, INC. | $20.06 | 2025 | Attruby |
| Cordis US Corp. | $17.05 | 2025 | Mynx Control |
| Gilead Sciences, INC. | $16.00 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.91 | 2022 | |
| Philips North America LLC | $12.62 | 2022 | |
| Allergan, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Ukpong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.